Last reviewed · How we verify

NCT06777628: Immunecheck

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

Recruiting now Last updated 16 January 2025
What this trial tests

trial testing Immunochemotherapy combined with antiangiogenic in Liver Cancer, Adult in 100 participants. Currently enrolling.

Timeline
15 September 2024
Primary endpoint
15 October 2026
15 October 2028

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date15 September 2024
Primary completion15 October 2026
Estimated completion15 October 2028
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Liver Cancer, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Immunochemotherapy combined with antiangiogenic

Trials testing the same drug.

Other recruiting trials for Liver Cancer, Adult

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06777628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing